Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

ABSTRACT:

Background & aims

In approximately 70% of patients with hepatocellular carcinoma (HCC) treated by resection or ablation, disease recurs within 5 years. Although gene expression signatures have been associated with outcome, there is no method to predict recurrence based on combined clinical, pathology, and genomic data (from tumor and cirrhotic tissue). We evaluated gene expression signatures associated with outcome in a large cohort of patients with early stage (Barcelona-Clinic Liver Cancer 0/A), single-nodule HCC and heterogeneity of signatures within tumor tissues.

Methods

We assessed 287 HCC patients undergoing resection and tested genome-wide expression platforms using tumor (n = 287) and adjacent nontumor, cirrhotic tissue (n = 226). We evaluated gene expression signat

SUBMITTER: Villanueva A 

PROVIDER: S-EPMC3081971 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature